0001209191-22-040274.txt : 20220701 0001209191-22-040274.hdr.sgml : 20220701 20220701164355 ACCESSION NUMBER: 0001209191-22-040274 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220701 FILED AS OF DATE: 20220701 DATE AS OF CHANGE: 20220701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Klencke Barbara CENTRAL INDEX KEY: 0001647647 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37490 FILM NUMBER: 221062043 MAIL ADDRESS: STREET 1: C/O SIERRA ONCOLOGY, INC. STREET 2: 1820 GATEWAY DRIVE, SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sierra Oncology, Inc. CENTRAL INDEX KEY: 0001290149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: (605) 376-8679 MAIL ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: ProNAi Therapeutics Inc DATE OF NAME CHANGE: 20040513 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-07-01 1 0001290149 Sierra Oncology, Inc. SRRA 0001647647 Klencke Barbara C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DR., SUITE 110 SAN MATEO CA 94404 0 1 0 0 Chief Medical Officer Common Stock 2022-07-01 4 D 0 10000 55.00 D 0 D Common Stock 2022-07-01 4 D 0 5000 55.00 D 0 I By spouse Stock Option (right to buy 268.20 2022-07-01 4 D 0 11744 0.00 D 2025-06-10 Common Stock 11744 0 D Stock Option (right to buy) 263.20 2022-07-01 4 D 0 2061 0.00 D 2016-03-08 Common Stock 2061 0 D Stock Option (right to buy) 72.80 2022-07-01 4 D 0 11399 0.00 D 2026-09-30 Common Stock 11399 0 D Stock Option (right to buy) 58.00 2022-07-01 4 D 0 1749 0.00 D 2027-03-06 Common Stock 1749 0 D Stock Option (right to buy) 94.40 2022-07-01 4 D 0 4508 0.00 D 2028-03-06 Common Stock 4508 0 D Stock Option (right to buy) 78.40 2022-07-01 4 D 0 4999 0.00 D 2029-03-04 Common Stock 4999 0 D Stock Option (right to buy) 13.31 2022-07-01 4 D 0 167091 0.00 D 2030-02-25 Common Stock 167091 0 D Stock Option (right to buy) 12.15 2022-07-01 4 D 0 49000 0.00 D 2030-08-12 Common Stock 49000 0 D Stock Option (right to buy) 16.73 2022-07-01 4 D 0 30000 0.00 D 2031-03-15 Common Stock 30000 0 D Stock Option (right to buy) 31.54 2022-07-01 4 D 0 50000 0.00 D 2032-03-14 Common Stock 50000 0 D The option fully vested on June 11, 2019. Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. The option fully vested on January 1, 2020. The option fully vested on September 30, 2019. The option fully vested on January 1, 2021. The option fully vested on January 1, 2022. The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. /s/ Mary Christina Thomson, Attorney-In-Fact for Barbara Klencke 2022-07-01